Related Experiment Videos
Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors
C B Pratt1, E C Douglass, W H Meyer
1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
Investigational New Drugs
|July 1, 1989
Abstract:
4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity. Maximum tolerated dosage was 36 mg/m2 given IV once every 3 weeks. Dose limiting toxicity was myelosuppression, which was severe and prolonged. Therapeutic benefits were not observed for these patients.